Renal anemia management in the chronic kidney disease population

Annals of Long-Term Care

Volumn 10, Issue 7, 2002, Pages 43-52

  Anand, Shaan ^a   Nissenson, Allen R ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARBEPOIETIN ALFA; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; HOSPITALIZATION; HUMAN; HYPERTENSION; MORTALITY; PREVALENCE; QUALITY OF LIFE; RENAL ANEMIA; REVIEW; UNITED STATES;

EID: 0036656123     PISSN: 15247929     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955-962.
2. Arora P, Kausz AT, Obrador GT, et al. Hospital utilization among chronic dialysis patients. J Am Soc Nephrol 2000;11:740-746.
3. United States Renal Data System. 1990 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; August 1990.
4. Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998;32:992-999. (Erratum appears in Am J Kidney Dis 2000;35:178.)
5. United States Renal Data System. 2000 Atlas of ESRD in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; 2000.
6. Pereira BJ. Introduction: New perspectives in chronic renal insufficiency. Am J Kidney Dis 2000;36(suppl 3):S1-S3.
7. Obrador GT, Ruthazer R, Arora P, et al. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 1999;10:1793-1800.
8. Zabetakis PM, Nissenson AR. Complications of chronic renal insufficiency: Beyond cardiovascular disease. Am J Kidney Dis 2000;36 (suppl 3): S31-S38.
9. Port FK. Morbidity and mortality in dialysis patients. Kidney Int 1994;46:1728-1737.
10. Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients. Am J Kidney Dis 1992;20:32-38.
11. Churchhill DN, Taylor DW, Cook RJ, et al. Canadian Hemodialysis Mortality Study. Am J Kidney Dis 1992;19:214-234.
12. Kopple JD. Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis 1994;24:1002-1009.
13. th ed. Philadelphia, PA: WB Saunders Co; 2000.
14. Foley RN, Parfrey PS, Hamett JD, et al. Clinical and echocardiographic disease in patients starting end-stage disease therapy. Kidney Int 1995;47:186-192.
15. Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capability and on renal function in predialytic uremic patients. Nephron 1992;60:390-396.
16. Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients: A double-blind placebocontrolled trial. Ann Intern Med 1989;110:108-114.
17. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin for predialysis chronic renal disease patients. Am J Kidney Dis 1995;24:548-554.
18. Nissenson AR. Epoetin and cognitive function. Am J Kidney Dis 1992;20:21-24.
19. Pereira BJ. Optimization of pre-ESRD care: The key to improved dialysis outcomes. Kidney Int 2000;57:351-365.
20. Bachmann S, LeHir M, Eckard KU. Co-localization of EPO mRNA and ecto-5′necleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce EPO. J Histochem Cytochem 1993;41:335-345.
21. Maxwell PH, Osmong MK, Pugh CW, et al. Identification of renal EPO-producing cells using transgenic mice. Kidney Int 1993;44:1149-1162.
22. Jelkman W. EPO: Structure, control of production, and function. Physiol Rev 1992;72:449-489.
23. Hara H, Ogawa M. Erythropoietic precursors in mice under erythropoietic stimulation and suppression. Exp Hematol 1977;5:141-148.
24. Schuster SJ, Cao J. Erythropoietin: Physiological basis for clinical applications. Vox Sang 1993;65:169-170.
25. Radtke HW, Claussner A, Erbes PM, et al. Serum erythropoietin concentration in chronic renal failure: Relationship to degree of anemia and excretory renal function. Blood 1979;54:877-884.
26. Kazmi WH, Kausz AT, Khan S, et al. Anemia: An early complication of chronic renal insufficiency. Am J Kidney Dis 2001;38:803-812.
27. Samak MJ, Levey AS. Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 2000; 35(suppl 1):S117-S131.
28. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999;34: 125-134.
29. Metivier F, Marchhias SJ, Guerin AP, et al. Pathophysiology of anaemia: Focus on the heart and blood vessels. Nephrol Dial Transplant 2000; 15(suppl 3):14-18.
30. Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-354.
31. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 2001; 37(suppl 1):S182-S238.
32. Wingard RL, Parker RA, Ismail N, et al. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995;25:433-439.
33. Dunea G, Swagel MA, Bodiwala U, et al. Intradialytic oral iron therapy. Int J Artif Organs 1994;17:261-264.
34. Piraio-Biroli G, Bothwell TH, Finch CA. Iron absorption. II. The absorption of radioiron administered with a standard meal in man. J Lab Clin Med 1958;51:24-36.
35. Bothwell TH, Piraio-Biroli G, Finch CA. Iron absorption. I. Factors influencing absorption. J Lab Clin Med 1958;51:24-36.
36. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-1699.
37. Hamstra RD, Block MH, Schrocket A. Intravenous iron dextran in clinical medicine. JAMA 1980;243:1723-1731.
38. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 2001;38:988-991.
39. Foley RN, Parfrey PS, Harnett JD. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
40. Greaves 5G, Gamble GD, Colins JF, et al. Determinants of left ventricular hypertrophy in chronic renal failure. Am J Kidney Dis 1994;24:768-776.
41. London GM, Fabiani, F, Marchais SJ, et al. Uremic cardiomyopathy: An inadequate left ventricular hypertrophy. Kidney Int 987;31:973-980.
42. Silberg J, Racine N, Barre P, et al. Regression of left ventricular hypertrophy following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990;6:1-4.
43. Nogao K, Tsuchihashi K, Ura M, et al. Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease. Can J Cardiol 1997;13:747-753.
44. Paganini EP In search of an optimal hematocrit level in dialysis patients: Rehabilitation and quality of life implications. Am J Kidney Dis 1994;24:S10-S16.
45. Besarab A, Balton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590.
46. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001;12:2465-2473
47. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;35:250-256.
48. Silverberg D, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of anemia of severe, resistant congestive heart disease improves cardiac and renal function and functional cardiac class, markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737-1744.
49. Portoles J, Torralbo A, Martin P, et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997;29:541-548.